TY - JOUR T1 - Patient-reported Outcomes in Polymyalgia Rheumatica JF - The Journal of Rheumatology JO - J Rheumatol SP - 795 LP - 803 DO - 10.3899/jrheum.110977 VL - 39 IS - 4 AU - ERIC L. MATTESON AU - HILAL MARADIT-KREMERS AU - MARCO A. CIMMINO AU - WOLFGANG A. SCHMIDT AU - MICHAEL SCHIRMER AU - CARLO SALVARANI AU - ARTUR BACHTA AU - CHRISTIAN DEJACO AU - CHRISTINA DUFTNER AU - HANNE SLOTT JENSEN AU - GYULA POÓR AU - NOVÁK PÁL KAPOSI AU - PETER MANDL AU - PETER V. BALINT AU - ZSUZSA SCHMIDT AU - ANNAMARIA IAGNOCCO AU - FABRIZIO CANTINI AU - CARLOTTA NANNINI AU - PIERLUIGI MACCHIONI AU - NICOLÒ PIPITONE AU - MONTSERRAT del AMO AU - GEORGINA ESPÍGOL-FRIGOLÉ AU - MARIA C. CID AU - VÍCTOR M. MARTÍNEZ-TABOADA AU - ELISABETH NORDBORG AU - HANER DIRESKENELI AU - SIBEL ZEHRA AYDIN AU - KHALID AHMED AU - BRIAN HAZELMAN AU - COLIN PEASE AU - RICHARD J. WAKEFIELD AU - RAASHID LUQMANI AU - ANDY ABRIL AU - RALPH MARCUS AU - NEIL J. GONTER AU - MEHRDAD MAZ AU - CYNTHIA S. CROWSON AU - BHASKAR DASGUPTA Y1 - 2012/04/01 UR - http://www.jrheum.org/content/39/4/795.abstract N2 - Objective. To prospectively evaluate the disease course and the performance of clinical, patient-reported outcome (PRO) and musculoskeletal ultrasound measures in patients with polymyalgia rheumatica (PMR). Methods. The study population included 85 patients with new-onset PMR who were initially treated with prednisone equivalent dose of 15 mg daily tapered gradually, and followed for 26 weeks. Data collection included physical examination findings, laboratory measures of acute-phase reactants, and PRO measures. Ultrasound evaluation was performed at baseline and Week 26 to assess for features previously reported to be associated with PMR. Response to corticosteroid treatment was defined as 70% improvement in PMR on visual analog scale (VAS). Results. At baseline, 77% had hip pain in addition to shoulder pain and 100% had abnormal C-reactive protein or erythrocyte sedimentation rate. On ultrasound, 84% had shoulder findings and 32% had both shoulder and hip findings. Response to corticosteroid treatment occurred in 73% of patients by Week 4 and was highly correlated with percentage improvement in other VAS measures. Presence of ultrasound findings at baseline predicted response to corticosteroids at 4 weeks. Factor analysis revealed 6 domains that sufficiently represented all the outcome measures: PMR-related pain and physical function, an elevated inflammatory marker, hip pain, global pain, mental function, and morning stiffness. Conclusion. PRO measures and inflammatory markers performed well in assessing disease activity in patients with PMR. A minimum set of outcome measures consisting of PRO measures of pain and function and an inflammatory marker should be used in practice and in clinical trials in PMR. ER -